CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo

Journal of Immunology

Volumn 177, Issue 5, 2006, Pages 3063-3073

  Haas, Karen M ^a   Sen, Suman ^a   Sanford, Isaac G ^a   Miller, Ann S ^a   Poe, Jonathan C ^a   Tedder, Thomas F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD22 ANTIGEN; FC RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD22; SIALIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BLOOD CELL; CELL INTERACTION; CELL MATURATION; CELL SURVIVAL; COMPLEMENT ACTIVATION; CONTROLLED STUDY; IN VIVO STUDY; INTERNALIZATION; LIGAND BINDING; LYMPH NODE; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SPLEEN CELL;

EID: 33747752856     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.5.3063     Document Type: Article

References (64)

1. Tedder, T. F., J. Tuscano, S. Sato, and J. H. Kehrt. 1997. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu. Rev. Immunol. 15: 481-504.
2. Erickson, L. D., L. T. Tygrett, S. K. Bhatia, K. H. Grabstein, and T. J. Waldschmidt. 1996. Differential expression of CD22 (Lyb8) on murine B cells. Int. Immunol. 8: 1121-1129.
3. Schulte, R. J., M. A. Campbell, W. H. Fischer, and B. M. Sefton. 1992. Tyrosine phosphorylation of CD22 during B cell activation. Science 258: 1001-1004.
4. Wilson, G. L., C. H. Fox, A. S. Fauci, and J. H. Kehrl. 1991. cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions. J. Exp. Med. 173: 137-146.
5. Poe, J. C., M. Fujimoto, P. J. Jansen, A. S. Miller, and T. F. Tedder. 2000. CD22 forms a quaternary complex with SHIP, Grb2 and She: a pathway for regulation of B lymphocyte antigen receptor-induced calcium flux. J. Biol. Chem. 275: 17420-17427.
6. Doody, G. M., L. B. Justement, C. C. Delibrias, R. J. Mathews, J. Lin, M. L. Thomas, and D. T. Fearon. 1995. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science 269: 242-244.
7. Lankester, A. C., G. M. van Schijndel, and R. A. van Lier. 1995. Hematopoietic cell phosphatase is recruited to CD22 following B cell antigen receptor ligation. J. Biol. Chem. 270: 20305-20308.
8. Campbell, M. A., and N. R. Klinman. 1995. Phosphotyrosine-dependent association between CD22 and protein tyrosine phosphatase 1C. Eur. J. Immunol. 25: 1573-1579.
9. 1 upon B cell activation. J. Exp. Med. 183: 547-560.
10. Blasioli, J., S. Paust, and M. L. Thomas. 1999. Definition of the sites of interaction between the protein tyrosine phosphatase SHP-1 and CD22. J. Biol. Chem. 274: 2303-2307.
11. Yohannan, J., J. Wienands, K. M. Coggeshall, and L. B. Justement. 1999. Analysis of tyrosine phosphorylation-dependent interactions between stimulatory effector proteins and the B cell co-receptor CD22. J. Biol. Chem. 274: 18769-18776.
12. Stamenkovic, I., and B. Seed. 1990. The B cell antigen CD22 mediates monocyte and erythrocyte adhesion. Nature 344: 74-77.
13. Law, C.-L., A. Aruffo, K. A. Chandran, R. T. Doty, and E. A. Clark. 1995. Ig domains 1 and 2 of murine CD22 constitute the ligand-binding domain and bind multiple sialylated ligands expressed on B and T cells. J. Immunol. 155: 3368-3376.
14. Engel, P., Y. Nojima, D. Rothstein, L.-J. Zhou, G. L. Wilson, J. H. Kehrl, and T. F. Tedder. 1993. The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils and monocytes. J. Immunol. 150: 4719-4732.
15. Kelm, S., A. Pelz, R. Schauer, M. T. Filbin, S. Tang, M.-E. de Bellard, R. L. Schnaar, J. A. Mahoney, A. Hartnell, P. Bradfield, and P. R. Crocker. 1994. Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily. Curr. Biol. 4: 965-972.
16. Sgroi, D., and I. Stamenkovic. 1994. A B-cell superfamily receptor with sialic acid-binding lectin activity. The Immunologist 2: 161.
17. Keim, S., R. Schaur, J. C. Manuguerra, H. J. Gross, and P. R. Crocker. 1994. Modifications of cell surface sialic acids modulate cell adhesion mediated by Sialoadhesin and CD22. Glycoconjugate J. 11: 576-585.
18. Engel, P., N. Wagner, A. Miller, and T. F. Tedder. 1995. Identification of the ligand binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. J. Exp. Med. 181: 1581-1586.
19. Peaker, C. J. G., and M. S. Neuberger. 1993. Association of CD22 with the B cell antigen receptor. Eur. J. Immunol. 23: 1358-1363.
20. Leprince, C., K. E. Draves, R. L. Geahlen, J. A. Ledbetter, and E. A. Clark. 1993. CD22 associates with the human surface IgM-B cell antigen receptor complex. Proc. Natl. Acad. Sci. USA 90: 3236-3240.
21. Pflugh, D. L., S. E. Maher, and A. L. M. Bothwell. 2002. Ly-6 superfamily members Ly-6A/E, Ly-6C, and Ly-6I recognize two potential ligands expressed by B lymphocytes. J. Immunol. 169: 5130-5136.
22. Stamenkovic, I., D. Sgroi, A. Aruffo, M. S. Sy, and T. Anderson. 1991. The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α2,6 sialyltransferase, CD75, on B cells. Cell 66: 1133-1144.
23. Han, S., B. E. Collins, P. Bengtson, and J. C. Paulson. 2005. Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking. Nat. Chem. Biol. 1: 93-97.
24. Poe, J. C., Y. Fujimoto, M. Hasegawa, K. M. Haas, A. S. Miller, I. G. Sanford, C. B. Bock, M. Fujimoto, and T. F. Tedder. 2004. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat. Immunol. 5: 1078-1087.
25. Sato, S., A. S. Miller, M. Inaoki, C. B. Bock, P. J. Jansen, M. L. K. Tang, and T. F. Tedder. 1996. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 5: 551-562.
26. O'Keefe, T. L., G. T. Williams, S. L. Davies, and M. S. Neuberger. 1996. Hyperresponsive B cells in CD22-deficient mice. Science 274: 798-801.
27. Otipoby, K. L., K. B. Andersson, K. E. Draves, S. J. Klaus, A. G. Fair, J. D. Kerner, R. M. Perlmutter, C.-L. Law, and E. A. Clark. 1996. CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 384: 634-637.
28. Nitschke, L., R. Carsetti, B. Ocker, G. Kohler, and M. C. Lamers. 1997. CD22 is a negative regulator of B-cell receptor signaling. Curr. Biol. 7: 133-143.
29. Lanoue, A., F. D. Batista, M. Stewart, and M. S. Neuberger. 2002. Interaction of CD22 with α2,6-linked sialoglycoconjugates: innate recognition of self to dampen B cell autoreactivity? Eur. J. Immunol. 32: 348-355.
30. Jin, L., P. A. McLean, B. G. Neel, and H. H. Wortis. 2002. Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling. J. Exp. Med. 195: 1199-1205.
31. Kelm, S., J. Gerlach, R. Brossmer, C.-P. Danzer, and L. Nitschke. 2002. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound. J. Exp. Med. 195, 1207-1213.
32. Symington, F. W., B. Subbarao, D. E. Mosier, and J. Sprent. 1982. Lyb-8.2: a new B cell antigen defined and characterized with a monoclonal antibody. Immunogenetics 16: 381-391.
33. Law, C.-L., R. M. Torres, H. A. Sundberg, R. M. E. Parkhouse, C. I. Brannan, N. G. Copeland, N. A. Jenkins, and E. A. Clark. 1993. Organization of the murine Cd22 locus: mapping to chromosome 7 and characterization of two alleles. J. Immunol. 151: 175-187.
34. Dunussi-Joannopoulos, K., G. E. Hancock, A. Kunz, M. Hegen, X. X. Zhou, B. J. Sheppard, J. Lamothe, E. Li, H. L. Ma, P. R. Hamann, et al. 2005. B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model. Blood 106: 2235-2243.
35. Nitschke, L., H. Floyd, D. J. P. Ferguson, and P. R. Crocker. 1999. Identification of CD22 ligands on bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B cells. J. Exp. Med. 189: 1513-1518.
36. Tuscano, J., P. Engel, T. F. Tedder, and J. H. Kehrl. 1996. Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation. Blood 87: 4723-4730.
37. Tuscano, J. M., A. Riva, S. N. Toscano, T. F. Tedder, and J. H. Kehrl. 1999. CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood 94: 1382-1392.
38. 90Y-DOT A-peptide-Lym-1 in lymphoma xenografts. Blood 101: 3641-3647.
39. Leonard, J. P., and B. K. Link. 2002. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin. Oncol. 29: 81-86.
40. Carnahan, J., P. Wang, R. Kendall, C. Chen, S. Hu, T. Boone, T. Juan, J. Talvenheimo, S. Montestruque, J. Sun, et al. 2003. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin. Cancer Res. 9: 3982S-3990S.
41. St. Clair, W. E., and T. F. Tedder. 2006. New prospects for autoimmune disease therapy: B cells on deathwatch. Arthritis Rheum. 54: 1-9.
42. Siegel, A. B., D. M. Goldenberg, A. Cesano, M. Coleman, and J. P. Leonard. 2003. CD22-directed monoclonal antibody therapy for lymphoma. Semin. Oncol. 30: 457-464.
43. Wessels, M. R., P. Butko, M. Ma, H. B. Warren, A. Lage, and M. C. Carroll. 1995. Studies of group B streptococcal infection in mice deficient in complement C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. USA 92: 11490-11494.
44. Martin, R. M., J. L. Brady, and A. M. Lew. 1998. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J. Immunol. Methods 212: 187-192.
45. Poe, J. C., K. M. Haas, J. Uchida, Y. Lee, M. Fujimoto, and T. F. Tedder. 2004. Severely-impaired B lymphocyte proliferation, survival and induction of the c-Myc:Cullin 1 ubiquitin ligase pathway resulting from CD22 deficiency on the C57BL/6 genetic background. J. Immunol. 172: 2100-2110.
46. Takai, T., M. Li, D. Sylvestre, R. Clynes, and J. V. Ravetch. 1994. FcRγ chain depletion results in pleiotrophic effector cell defects. Cell 76: 519-529.
47. Ravetch, J. V., and R. A. Clynes. 1998. Divergent roles for Fc receptors and complement in vivo. Annu. Rev. Immunol. 16: 421-432.
48. Nimmerjahn, F., P. Bruhns, K. Horiuchi, and J. V. Ravetch. 2005. FcγRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23: 41-51.
49. Collins, B. E., O. Blixt, A. R. DeSieno, N. Bovin, J. D. Marth, and J. C. Paulson. 2004. Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc. Natl. Acad. Sci. USA 101: 6104-6109.
50. Collins, B. E., B. A. Smith, P. Bengtson, and J. C. Paulson. 2006. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nat. Immunol. 7: 199-206.
51. Shan, D., and O. W. Press. 1995. Constitutive endocytosis and degradation of CD22 by human B cells. J. Immunol. 154: 4466-4475.
52. John, B., B. R. Herrin, C. Raman, Y. Wang, K. R. Bobbin, B. A. Brody, and L. B. Justement. 2003. The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction. J. Immunol. 170: 3534-3543.
53. Ghetie, M.-A., R. D. May, M. Till, J. W. Uhr, V. Ghetie, P. P. Knowles, M. Relf, A. Brown, P. M. Wallace, G. Janossy, et al. 1988. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res. 48: 2610-2617.
54. Samardzic, T., D. Marinkovic, C.-P. Danzer, J. Gerlach, L. Nitschke, and T. Wirth. 2002. Reduction of marginal zone B cells in CD22-deficient mice. Eur. J. Immunol. 32: 561-567.
55. Danzer, C. P., B. E. Collins, O. Blixt, J. C. Paulson, and L. Nitschke. 2003. Transitional and marginal zone B cells have a high proportion of unmasked CD22: implications for BCR signaling. Int. Immunol. 15: 1137-1147.
56. Uchida, J., Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199: 1659-1669.
57. Hamaguchi, Y., J. Uchida, D. W. Cain, G. M. Venturi, J. C. Poe, K. M. Haas, and T. F. Tedder. 2005. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J. Immunol. 7: 4389-4399.
58. Hamaguchi, Y., Y. Xiu, K. Komura, F. Nimmerjahn, and T. F. Tedder. 2006. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203: 743-753.
59. Yazawa, N., Y. Hamaguchi, J. C. Poe, and T. F. Tedder. 2005. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc. Natl. Acad. Sci. USA 102: 15178-15183.
60. Amano, H., E. Amano, T. Moll, D. Marinkovic, N. Ibnou-Zekri, E. Martinez-Soria, I. Semac, T. Wirth, L. Nitschke, and S. Izui. 2003. The Yaa mutation promoting murine lupus causes defective development of marginal zone B cells. J. Immunol. 170: 2293-2301.
61. Carter, R. H., G. M. Doody, J. B. Bolen, and D. T. Fearon. 1997. Membrane IgM-induced tyrosine phosphorylation of CD19 requires a CD19 domain that mediates association with components of the B cell antigen receptor complex. J. Immunol. 158: 3062-3069.
62. Zhang, M., and A. Varki. 2004. Cell surface sialic acids do not affect primary CD22 interactions with CD45 and surface IgM nor the rate of constitutive CD22 endocytosis. Glycobiology 14: 939-949.
63. syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22. Eur. J. Immunol. 26: 1246-1252.
64. Stein, R., E. Belisle, H. J. Hansen, and D. M. Goldenberg. 1993. Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2. Cancer Immunol. Immunother. 37: 293-298.